Several years ago, drug maker Gilead Science Inc. applied for a Chinese patent for the use of Remdesivir against coronaviruses. Remdesivir was originally intended to treat Ebola but was also shown to inhibit coronaviruses, such as SARS.
Recently, scientists at the government-run Wuhan Institute of Virology, along with a military laboratory, reportedly applied to patent the use of Remdesivir to treat the specific coronavirus, Covid-19, which is being blamed for the recent outbreak.
No decision has been made regarding the Gilead patent application. However, if approved, as a member of the WTO, the Chinese government may be able to use the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement to obtain a compulsory licence for Remdesivir. If so, the Chinese government would decide, subject to any appeal, what payment Gilead would receive.
In considering the Wuhan Institute’s application, the Chinese patent office will likely have to consider issues of anticipation and obviousness.
For its part, Gilead is helping end the current crisis by working with health authorities. The company is reportedly providing Remdesivir for emergency use in clinical trials.
In vitro studies of Remdesivir and chloroquine have been published in Cell Research, stating that the mixture is effective for inhibiting Covid-19.
Author: Matthew Buck
Authors
Expertise
Insights
-
Intellectual Property Litigation
Sportswear Brand Sues University Over Similarities in Merchandise
As reported by the Associated Press, Columbia Sportswear has sued Columbia University, claiming that the university infringed the sportswear company’s trademark and breached an agreement between the… -
Intellectual Property Litigation
Call Dropped: Verizon Cuts Deal in $175M Patent Clash
Verizon and Headwater Research LLC have reportedly agreed to settle a patent infringement lawsuit that ended with a $175 million USD jury verdict against the telecom giant. Headwater, a… -
Intellectual Property Litigation
Nintendo Secures Copyright Victory in China
In a recent copyright infringement case, the Jiangsu High Court ruled in favor of Nintendo, awarding the company approximately $28,000 USD, or 200,000 RMB, and an injunction against an unnamed… -
Intellectual Property Litigation
Regulatory Updates – Impacts of Global Tariffs on Pharmaceuticals
Recent tariff measures affecting pharmaceutical products and ingredients have introduced new compliance and cost considerations for manufacturers, distributors, and importers operating in Canada and… -
Intellectual Property Litigation
US Appeals Court: Supertramp Songwriter Must "Give a Little Bit"
As reported by Reuters, the 9th U.S. Circuit Court of Appeals has ruled that Roger Hodgson, the former Supertramp singer and songwriter, must compensate three former band members for a share of… -
Intellectual Property Litigation
Fallout from Trade Secret Theft in Taiwan
As reported by Reuters, three former employees of Taiwan Semiconductor Manufacturing Company ("TSMC") were charged with violating security law and other offences in Taiwan. The prosecutors have…